Jean-Pierre Sommadossi

CIK: 0001296995

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (33.3%)

Position reduction

Option Exercises (M)3 (33.3%)

Derivative conversions

Awards (A)1 (11.1%)

Compensation grants

Other (G, F, J, C, D, …)2 (22.2%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

AVIR

Atea Pharmaceuticals, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (9 total)

AVIR
Atea Pharmaceuticals, Inc.
Feb 3, 2026
Exercise(M)
Direct
300K shares at avg. $1.24$372K
AVIR
Atea Pharmaceuticals, Inc.
Jan 31, 2026
Exercise(M)
Direct
273K shares-
AVIR
Atea Pharmaceuticals, Inc.
Jan 31, 2026
Tax Payment(F)
Direct
106.1K shares at avg. $4.24$450K
AVIR
Atea Pharmaceuticals, Inc.
Jan 31, 2025
Award(A)
Direct
99.5K shares-
AVIR
Atea Pharmaceuticals, Inc.
Jan 31, 2025
Exercise(M)
Direct
173.5K shares-
AVIR
Atea Pharmaceuticals, Inc.
Jan 31, 2025
Tax Payment(F)
Direct
88.6K shares at avg. $3.06$271K
AVIR
Atea Pharmaceuticals, Inc.
Sep 19, 2024
Sale(S)
Indirect
1.8K shares at avg. $4.00$7K
AVIR
Atea Pharmaceuticals, Inc.
Sep 18, 2024
Sale(S)
Indirect
22.2K shares at avg. $4.03$89K
AVIR
Atea Pharmaceuticals, Inc.
Sep 17, 2024
Sale(S)
Indirect
33.9K shares at avg. $4.05$137K

		Type	Shares	Price		Ownership
Feb 3, 2026	AVIR Atea Pharmaceuticals, Inc.	Exercise(M)	300,000	$1.24	$372,000	Direct
Jan 31, 2026	AVIR Atea Pharmaceuticals, Inc.	Exercise(M)	272,983	-	$0	Direct
Jan 31, 2026	AVIR Atea Pharmaceuticals, Inc.	Tax Payment(F)	106,093	$4.24	$449,834	Direct
Jan 31, 2025	AVIR Atea Pharmaceuticals, Inc.	Award(A)	99,517	-	-	Direct
Jan 31, 2025	AVIR Atea Pharmaceuticals, Inc.	Exercise(M)	173,467	-	-	Direct
Jan 31, 2025	AVIR Atea Pharmaceuticals, Inc.	Tax Payment(F)	88,601	$3.06	$271,119	Direct
Sep 19, 2024	AVIR Atea Pharmaceuticals, Inc.	Sale(S)	1,841	$4.00	$7,367	Indirect
Sep 18, 2024	AVIR Atea Pharmaceuticals, Inc.	Sale(S)	22,187	$4.03	$89,469	Indirect
Sep 17, 2024	AVIR Atea Pharmaceuticals, Inc.	Sale(S)	33,941	$4.05	$137,318	Indirect

1-9 of 9 transactions

About Sommadossi Jean-Pierre

Sommadossi Jean-Pierre (SEC CIK 0001296995) files insider reports with the SEC as President, CEO, and Chairman of Atea Pharmaceuticals, Inc. (AVIR).

Signal8 holds 3 ownership filings by Sommadossi Jean-Pierre, all Form 4s, filed between Sep 19, 2024 and Feb 3, 2026. Those filings report 9 transactions, from Sep 17, 2024 to Feb 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Sommadossi Jean-Pierre's filings is in BOSTON, MA.

Recent filings by Sommadossi Jean-Pierre

Feb 3, 2026: Option exercise of AVIR shares (Form 4, code M).
Jan 31, 2026: Option exercise of AVIR shares (Form 4, code M).
Jan 31, 2026: Tax withholding of AVIR shares (Form 4, code F).
Jan 31, 2025: Grant or award of AVIR shares (Form 4, code A).
Jan 31, 2025: Option exercise of AVIR shares (Form 4, code M).

Other insiders filing for Atea Pharmaceuticals, Inc. (AVIR)

Lucidi Bruno, Director
BERGER FRANKLIN M, Director
Berman Howard, Director
DUNCAN BARBARA GAYLE, Director
Polsky Bruce, Director
Murphy Polly A., Director

How to read Form 4 transaction codes